Nuo Therapeutics Gross Margin Growth & History (AURX)

Nuo Therapeutics's gross margin was 66.94% for fiscal 2025.

View full Nuo Therapeutics company overview

Nuo Therapeutics annual gross margin history

Nuo Therapeutics annual gross margin

Fiscal yearPeriod endedGross marginChange (percentage points)
20252025-12-3166.94%−10.88 pp
20242024-12-3177.82%−1.46 pp
20232023-12-3179.28%−3.60 pp
20222022-12-3182.88%−5.23 pp
20182018-12-3188.11%+139.42 pp
20172017-12-31−51.31%−82.10 pp
20152015-12-3130.79%+18.02 pp
20142014-12-3112.77%−14.18 pp
20132013-12-3126.95%−36.00 pp
20122012-12-3162.95%+0.57 pp
20112011-12-3162.37%+3.61 pp
20102010-12-3158.76%

Nuo Therapeutics gross margin trends

Over the last five reported fiscal years, Nuo Therapeutics's gross margin increased from −51.31% to 66.94%, a change of +118.25 percentage points. The latest reported quarter, Q2 2026, shows 66.14%.

About the metric

What gross margin means

Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.

Calculation and source

How gross margin is calculated

TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Nuo Therapeutics filings at SEC.gov ↗